BGB-15025
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BGB-15025, covering 2026-02-20 to 2026-02-20. Get the full timeline:
Most recent: Clinical Trial Update: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors [Phase 1]